Watson Pharmaceuticals (Actavis Inc.) / Actavis plc

Generic Pharmaceuticals (Multi-Therapeutic)

$8.0B Pro-forma 2012 combined revenue (Watson + Actavis)

Disease Overview

Generic pharmaceuticals provide low-cost copies of branded drugs after patent expiry, spanning every major therapeutic area (cardiovascular, CNS, anti-infectives, oncology, women's health, and more). The 2012 generics market was consolidating rapidly under pricing pressure from US payers and global procurement initiatives, driving a wave of mega-mergers among Teva, Sandoz (Novartis), Mylan, Watson, and Hospira.

Competitive Landscape

Pre-deal, Watson was a US-centric #4 generics player behind Teva, Sandoz, and Mylan. Actavis was the privately-held Switzerland-based #5 with deep European/EM exposure but limited US scale. The combination created the world's #3 generics company by revenue (~$8B pro forma 2012), shifting Watson's international mix from 16% to 40% of generic revenues and giving it top-3 positions in 11 markets including Russia, Central/Eastern Europe, and the Nordics. Jefferies analyst Corey Davis wrote that 'WPI is now much more competitive with Teva and Sandoz for a global presence, and in our opinion, leapfrogs Mylan'. The FTC required divestiture of 18 generic products to Sandoz and Par Pharmaceutical to settle competitive overlap concerns spanning hypertension, diabetes, anxiety, and ADHD generics. Watson rebranded as Actavis post-close, then went on a transformative M&A spree (Warner Chilcott 2013, Forest 2014, Allergan 2015), eventually selling the global generics business to Teva in 2016 and re-emerging as the branded specialty player Allergan plc.